INSTEP Trial

Influence of NSAID on Short Term Efficacy of Pleurodesis for recurrent pneumothorax

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000082606

Acronym

INSTEP

Enrollment

100

Registered

2005-08-05

Start date

2004-12-15

Completion date

2024-06-30

Last updated

2024-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

For pain relief after VATS pleurodesis, patients are given either Celebrex or Placebo for 5 days plus any other required analgesics. We aim to determine whether there is any difference in failure of the lung to adhere to the lining of the chest.

Interventions

Celebrex 200mg bd 5 days

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with surgical indication for pleurodesis due to recurrent or persistent pneumohtorax

Exclusion criteria

Chronic NSAID usage that cannot be stopped for more than 24 hours prior to surgery. Renal impairment

Outcome results